Therapeutic Management of Small Cell Lung Cancer

Fewer Toxic Reactions With Lower Chemotherapeutic Drug Dosages

Margaret Anne Kessinger, John F. Foley, Henry M. Lemon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A treatment protocol for small cell lung cancer used attenuated drug dosages in an attempt to reduce toxic reactions without compromising effectiveness. Treatment consisted of cyclophosphamide, 50 mg orally daily, methotrexate, 1.25 mg orally daily, procarbazine hydrochloride, 50 mg orally daily, and vincristine sulfate, 10 μg/kg intravenously weekly, and was continued until relapse or for two years. Patients with limited disease were given concurrent radiation (4,000 to 5,000 rad, using standard fractionation) to the primary lesion and draining nodes. Fifty patients were evaluable for toxic reactions and survival: 22 with limited and 28 with extensive disease. Fifty-four percent of the patients with extensive disease responded; one (4%) had a complete response. Median survival of the patients with extensive disease was 20 weeks. Ninety-five percent of the patients with limited disease responded; 57% had a complete response. Median survival of these patients was 55 weeks; one-year survival was 59%, and 18-month survival was 36%. Three patients have discontinued therapy without relapse for 48, 22, and seven months. One patient remains disease free after undergoing therapy for 84 weeks. There were no treatment-related deaths, and only 4% of patients experienced WBC count nadirs of less than 1,000/cu mm. Patients with limited disease had long-term survivals comparable with those of other more toxic protocols.

Original languageEnglish (US)
Pages (from-to)3188-3191
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Volume250
Issue number23
DOIs
StatePublished - Dec 16 1983

Fingerprint

Poisons
Small Cell Lung Carcinoma
Pharmaceutical Preparations
Survival
Therapeutics
Procarbazine
Recurrence
Vincristine
Clinical Protocols
Methotrexate
Cyclophosphamide
Radiation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic Management of Small Cell Lung Cancer : Fewer Toxic Reactions With Lower Chemotherapeutic Drug Dosages. / Kessinger, Margaret Anne; Foley, John F.; Lemon, Henry M.

In: JAMA: The Journal of the American Medical Association, Vol. 250, No. 23, 16.12.1983, p. 3188-3191.

Research output: Contribution to journalArticle

@article{7b5d04fdff0e41b28d7482ba54f78737,
title = "Therapeutic Management of Small Cell Lung Cancer: Fewer Toxic Reactions With Lower Chemotherapeutic Drug Dosages",
abstract = "A treatment protocol for small cell lung cancer used attenuated drug dosages in an attempt to reduce toxic reactions without compromising effectiveness. Treatment consisted of cyclophosphamide, 50 mg orally daily, methotrexate, 1.25 mg orally daily, procarbazine hydrochloride, 50 mg orally daily, and vincristine sulfate, 10 μg/kg intravenously weekly, and was continued until relapse or for two years. Patients with limited disease were given concurrent radiation (4,000 to 5,000 rad, using standard fractionation) to the primary lesion and draining nodes. Fifty patients were evaluable for toxic reactions and survival: 22 with limited and 28 with extensive disease. Fifty-four percent of the patients with extensive disease responded; one (4{\%}) had a complete response. Median survival of the patients with extensive disease was 20 weeks. Ninety-five percent of the patients with limited disease responded; 57{\%} had a complete response. Median survival of these patients was 55 weeks; one-year survival was 59{\%}, and 18-month survival was 36{\%}. Three patients have discontinued therapy without relapse for 48, 22, and seven months. One patient remains disease free after undergoing therapy for 84 weeks. There were no treatment-related deaths, and only 4{\%} of patients experienced WBC count nadirs of less than 1,000/cu mm. Patients with limited disease had long-term survivals comparable with those of other more toxic protocols.",
author = "Kessinger, {Margaret Anne} and Foley, {John F.} and Lemon, {Henry M.}",
year = "1983",
month = "12",
day = "16",
doi = "10.1001/jama.1983.03340230040024",
language = "English (US)",
volume = "250",
pages = "3188--3191",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "23",

}

TY - JOUR

T1 - Therapeutic Management of Small Cell Lung Cancer

T2 - Fewer Toxic Reactions With Lower Chemotherapeutic Drug Dosages

AU - Kessinger, Margaret Anne

AU - Foley, John F.

AU - Lemon, Henry M.

PY - 1983/12/16

Y1 - 1983/12/16

N2 - A treatment protocol for small cell lung cancer used attenuated drug dosages in an attempt to reduce toxic reactions without compromising effectiveness. Treatment consisted of cyclophosphamide, 50 mg orally daily, methotrexate, 1.25 mg orally daily, procarbazine hydrochloride, 50 mg orally daily, and vincristine sulfate, 10 μg/kg intravenously weekly, and was continued until relapse or for two years. Patients with limited disease were given concurrent radiation (4,000 to 5,000 rad, using standard fractionation) to the primary lesion and draining nodes. Fifty patients were evaluable for toxic reactions and survival: 22 with limited and 28 with extensive disease. Fifty-four percent of the patients with extensive disease responded; one (4%) had a complete response. Median survival of the patients with extensive disease was 20 weeks. Ninety-five percent of the patients with limited disease responded; 57% had a complete response. Median survival of these patients was 55 weeks; one-year survival was 59%, and 18-month survival was 36%. Three patients have discontinued therapy without relapse for 48, 22, and seven months. One patient remains disease free after undergoing therapy for 84 weeks. There were no treatment-related deaths, and only 4% of patients experienced WBC count nadirs of less than 1,000/cu mm. Patients with limited disease had long-term survivals comparable with those of other more toxic protocols.

AB - A treatment protocol for small cell lung cancer used attenuated drug dosages in an attempt to reduce toxic reactions without compromising effectiveness. Treatment consisted of cyclophosphamide, 50 mg orally daily, methotrexate, 1.25 mg orally daily, procarbazine hydrochloride, 50 mg orally daily, and vincristine sulfate, 10 μg/kg intravenously weekly, and was continued until relapse or for two years. Patients with limited disease were given concurrent radiation (4,000 to 5,000 rad, using standard fractionation) to the primary lesion and draining nodes. Fifty patients were evaluable for toxic reactions and survival: 22 with limited and 28 with extensive disease. Fifty-four percent of the patients with extensive disease responded; one (4%) had a complete response. Median survival of the patients with extensive disease was 20 weeks. Ninety-five percent of the patients with limited disease responded; 57% had a complete response. Median survival of these patients was 55 weeks; one-year survival was 59%, and 18-month survival was 36%. Three patients have discontinued therapy without relapse for 48, 22, and seven months. One patient remains disease free after undergoing therapy for 84 weeks. There were no treatment-related deaths, and only 4% of patients experienced WBC count nadirs of less than 1,000/cu mm. Patients with limited disease had long-term survivals comparable with those of other more toxic protocols.

UR - http://www.scopus.com/inward/record.url?scp=0021076702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021076702&partnerID=8YFLogxK

U2 - 10.1001/jama.1983.03340230040024

DO - 10.1001/jama.1983.03340230040024

M3 - Article

VL - 250

SP - 3188

EP - 3191

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 23

ER -